Navigation Links
Stronger Backing for Drug-Coated Stents

New research proves drug-coated stents effectively combat death, heart attack and repeat procedures in the real world.//

A new study from researchers in the Netherlands indicates that patients in clinical trials of drug-coated stents represented a very select group of the total population. This new study takes a closer look at the effects of drug-coated stents on real-world patients, patients the researchers say tend to be older and sicker than those selected for clinical trials.

The study included more than 500 patients with previously untreated blocked arteries who were treated with drug-eluting stents. An additional 450 patients with comparable blockages were treated with bare metal stents. Sixty-eight percent of the patients in this trial did not meet the selection criteria of previous clinical trials.

Results of the one-year study show 9.7 percent of patients who received drug-eluting stents had a major adverse cardiac event, compared with 14.8 percent of patients treated with bare metal stents. Only 3.7 percent of patients with drug-eluting stents experienced renarrowing of the treated vessel, a common complication that leads to corrective procedures. However, 10.9 percent of patients with bare metal stents required repeat procedures to correct renarrowing of the artery.

Lead investigator Patrick W. Serruys, M.D., Ph.D., from Erasmus Medical Center in the Netherlands, says, “The treatment effects -- particularly the reduction of re-interventions -- were similar across very different subgroups of patients.” He says drug-eluting stents are the next major step in interventional cardiology.

In an accompanying editorial, David P. Fason, M.D., from the University of Chicago, says the research results “go a long way in re-assuring the practitioner that drug-eluting stents are in fact safe and effective in a wide variety of patients undergoing ‘real world’ angioplasty.” He concludes that the next step shoul d be a mandatory registry established by the Food and Drug Administration to report problems.


Related medicine news :

1. Health Care Ties To Get Stronger Between India And Britain
2. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
3. Stronger Doses Fewer Administration for Breast Cancer
4. Stronger Quadricep Controls Knee Osteoarthritis
5. Old Indian Advice Has A Scientific Backing Now!
6. Fury over Backing of Health Shake-up
7. Failure of Drug-Coated Stent
8. Drug-Coated Stent
9. Drug-Coated Stents – Proven to be More Effectiv
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Drug-Coated Stents – Proven to be More Effectiv
Post Your Comments:

(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... European Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, ... (UNON) for the opening of the 5th African Network for Drugs and Diagnostics ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: